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Background and Objective: Chronic widespread pain (CWP) is a significant burden 
in communities. Understanding the impact of population-dependent (e.g., age, gender) 
and context-dependent (e.g., survey method, region, inequality level) factors have on 
CWP prevalence may provide a foundation for population-based strategies to address 
CWP. Therefore, the purpose of this study was to estimate the global prevalence of 
CWP and evaluate the population and contextual factors associated with CWP.  
Databases and Data Treatment: A systematic review of CWP prevalence studies 
(1990-2016) in the general population was undertaken. Meta-analyses were conducted 
to determine CWP prevalence, and study population data and contextual factors were 
evaluated using a meta-regression.  
Results: Thirty-nine manuscripts met the inclusion criteria. Study CWP prevalence 
ranged from 1.4%-24.0%, with CWP prevalence in men ranging from 0.8%-15.3% 
and 1.7%-22.1% in women. Estimated overall CWP prevalence was 9.6% (8.0-
11.2%). Meta-regression analyses showed gender, United Nations country 
development status, and human development index (HDI) influenced CWP 
prevalence, while survey method, region, methodological and reporting quality, and 
inequality showed no significant effect on the CWP estimate. 
Conclusion: Globally CWP affects one in ten individuals within the general 
population, with women more likely to experience CWP than men. HDI was noted to 
be the socioeconomic factor related to CWP prevalence, with those in more developed 
countries having a lower CWP prevalence than those in less developed countries. 
Most CWP estimates were from developed countries, and CWP estimates from 





countries with a lower socioeconomic position is needed to further refine the global 
estimate of CWP.  
What does this study add? This systematic review and meta-analysis updates the 
current global CWP prevalence by examining the population-level (e.g., age, gender) 
and contextual (e.g., country development status; survey style; reporting and 
methodologic quality) factors associated with CWP prevalence. This analyses 
provides evidence to support higher levels of CWP in countries with a lower 
socioeconomic position relative to countries with a higher socioeconomic position. 
 
Key Words: Chronic widespread pain, general population, class, socioeconomic 
position, systematic review, epidemiology. 





1. Introduction 1 
 2 
The estimated prevalence of chronic pain, defined as pain lasting more than three 3 
months, is between 35% and 50% worldwide (Elzahaf et al., 2012). Epidemiologic 4 
studies of chronic pain have tended to centre on one joint, such as the foot, knee, low 5 
back and shoulder (Freburger et al., 2009; Hiller et al., 2012; Hurley et al., 2012; Roh 6 
et al., 2012). However, some individuals experience pain all over the body, and in 7 
1990, the term “chronic widespread pain” (CWP) was defined as pain lasting longer 8 
than 3 months, with pain being on the left and right sides of the body, above and 9 
below the waist, and on the axial skeleton (Wolfe et al., 1990). With the formal 1990 10 
definition of CWP, a recent review suggested the worldwide estimate of CWP ranges 11 
from 10.6% to 11.8% (Mansfield et al., 2016).  12 
 CWP adversely affects quality of life, mobility and physical function (Nicholl 13 
et al., 2009). Further, CWP is a common condition associated with fibromyalgia 14 
syndrome (FMS) and is noted to be an early indicator of FMS (Forseth et al., 1999; 15 
Toda 2011). CWP and FMS can place significant challenges onto the healthcare 16 
system, and inconsistent messages exist within the literature with regard to the most 17 
effective diagnosis and management strategies (Lee et al., 2014). Living with CWP 18 
can have significant cost implications to not only the government but also the 19 
individual patient in terms of lost work, benefits and medical costs (Barham 2012; 20 
Gaskin and Richard 2012; Henschke et al., 2015). In Europe approximately 1.5-3.0% 21 
of their annual gross domestic product (GDP) is spent on chronic pain (Barham 2012; 22 
Gaskin and Richard 2012). In the United States (US), chronic pain costs between 23 
$560 and $635 billion annually, a cost higher than heart disease ($309b), cancer 24 





($243b) and diabetes ($188b). Further, direct and indirect annual costs of CWP per 25 
patient in the US are estimated to be $12,428 (Schaefer et al., 2015).  26 
Since the inception of the ACR definition in 1990, researchers have estimated 27 
CWP at the local and country level in order to determine burden of CWP in the 28 
population (Mansfield et al., 2016). While this prior study of global CWP prevalence 29 
addressed a significant gap, the current review and analyses aims to build upon it to 30 
update the CWP estimate and to evaluate study population (e.g., age, gender) and 31 
contextual (e.g., country development status; survey style; methodology and reporting 32 
quality) factors associated with CWP prevalence.  33 
 34 
  35 





2.0 Methodology 36 
 37 
2.1 Search Strategy 38 
A primary literature search of electronic databases was performed to extract 39 
epidemiological studies of the global prevalence of chronic widespread pain (CWP) in 40 
the general adult population (1st January 1990 to 5th April 2017). The lower year 41 
limit of 1990 was applied to align with the seminal publication defining CWP (Wolfe 42 
et al., 1990).  43 
Electronic databases included in the study were PSYCinfo, MEDLINE, 44 
Cumulative Index to Nursing and Allied Health Literature (CINAHL), The Allied and 45 
Complementary Database (AMED), Cochrane library, PubMed and OVID. To 46 
identify publications related to the prevalence of CWP, there were three criterion 47 
components of the search strategy: (1) outcome, (2) methodology, and (3) population, 48 
which were combined using Boolean operators. Outcome search terms were 49 
associated with ‘chronic pain,’ and methodology search terms were associated with 50 
‘prevalence,’ and to limit the likelihood of sub-populations a ‘NOT’ operator of 51 
‘cancer’ or ‘diabetes’ was used to reduce publications that were not focused on the 52 
general population. No language restrictions were applied. 53 
 54 
2.2. Selection Criteria and Data Extraction 55 
Set inclusion and exclusion were specified a priori and applied in three steps (Table 56 
1). In the first step, studies were eliminated if it was evident from the title that criteria 57 
regarding outcome, methodology, and population were not satisfied. At this title 58 
stage, one reviewer (PA) eliminated publications, with a second reviewer (JLR) 59 
verifying these results. In the second step, two reviewers (PA and JLR) independently 60 





reviewed abstracts to determine if inclusion criteria were met. From the abstract stage, 61 
full-texts of the manuscripts were obtained and reviewed for inclusion, with study 62 
methods evaluated against the set criteria. Manuscripts written in languages other than 63 
English were included and were reviewed by others comfortable with the language. 64 
Prevalence data was recorded for CWP in the general population along with separate 65 
figures for gender and age as well as weighted and unweighted where applicable.  If 66 
data from the same manuscript were reported in multiple publications, data are 67 
reported as one study.  68 
 69 
2.3 Assessment of Study Quality 70 
Two reviewers (JLR and PA) independently evaluated the included studies based on 71 
the criteria in the Strengthening the Reporting of Observational Studies in 72 
Epidemiology (STROBE) checklist (Von Elm et al., 2007), a reliable method for 73 
reporting observational studies (Tate and Douglas 2011). For this analysis, the 74 
STROBE was modified to include 12 items. Each item was scored independently as 75 
either ‘Identified’ (1 point) or ‘Not Identified’ (0 point), and scoring was discussed to 76 
reach consensus. The points from the modified STROBE were summed (Table S1), 77 
and studies were considered as having low risk of bias if they were found to be of 78 
high quality (≥9/12) and high risk of bias if they were found to be of low quality 79 
(≤8/12), with this cut-point near the 80% quality cut-point (Slavin 1995). 80 
 81 
 82 
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2.4 CWP Study Contextual Data 84 
Additional contextual data was added to evaluate factors associated to the CWP 85 
prevalence. Contextual data included were the country’s United Nations (UN) 86 
development status (i.e., developed and developing country)  (UN 2012), World 87 
Health Organisation (WHO) region (WHO 2017), Human Development Index (HDI) 88 
(HDR 2016), and Gini index (TWB 2017).  89 
The HDI is a composite measure of three basic dimensions: life expectancy, 90 
education, and per capita income, and it is an indicator of the country’s support 91 
systems and its citizen’s health, personal, social, and political freedom, and well-92 
being. The GINI index is a measure of statistical dispersion used to represent the net 93 
income distribution within a country, and it can define a country’s level of rich-to-94 
poor inequality. GINI index values can range between 0 and 1, with 0 representing 95 
perfect equality and 1 representing perfect inequality, but in practice, it ranges from 96 
approximately 0.2 to 0.7 (TWB 2017). The HDI and Gini values and the country’s 97 
development status were based on the year of the data collection, and when an 98 
estimate was not available for the study year, the closest year to the study collection 99 
period was used. 100 
 101 
2.5 Data Analysis 102 
A meta-analysis combined the CWP prevalences of the individual studies to estimate 103 
the prevalence of CWP for the overall population sample as well as by gender, age, 104 
WHO region and survey method. Univariate meta-analyses were performed on all 105 
individual and contextual variables to determine if there was a significant effect of the 106 
variable on CWP prevalence. Statistical significance was set to p<0.05. There was no 107 
multiple testing correction, which may increase the likelihood of false positive; 108 





however it is a valid means for exploring value of each variable in regression 109 
modelling (Bender and Lange 2001). I2 statistical calculations were conducted to 110 
examine the heterogeneity between all studies and subgroups.  The 95% confidence 111 
intervals were calculated using the Wilson score method with continuity corrections. 112 
All statistical analyses were performed using R version 3.3.1.  113 
 114 
  115 





3.0 Results 116 
 117 
3.1 Study Selection 118 
Implementation of the search strategy yielded 12,097 records, of which 5,768 were 119 
duplicates (Figure 1). Screening of titles excluded 6,038 manuscripts, leaving 291 120 
records for the abstract stage. At the abstract stage an additional 120 titles were 121 
excluded, leaving 171 for the full-text stage. Full-text screening excluded 132 122 
manuscripts, leaving 39 manuscripts (30 unique studies with 41 CWP population-123 
level estimates) with a total of 632,937 participants. Study sample size ranged from 124 
361 (Santos et al., 2010) to 501,733 (Walker-Bone et al., 2016). Twenty-six studies 125 
included both genders, whereas three studies included only women (Abusdal et al., 126 
1997a; Abusdal et al., 1997b; Schochat and Beckmann 2003; Topbas et al., 2005) and 127 
one study included only men (Lee et al., 2010; Macfarlane et al., 2009b). Six studies 128 
failed to report gender characteristics (Bergman et al., 2001; Gerdle et al., 2008; 129 
Hagen et al., 2005; Lindell et al., 2000; Papageorgiou et al., 2002; Scudds et al., 2006; 130 
Wolfe et al., 1995). Participants’ age in the included studies ranged from 15-94 years.  131 
 132 
Figure 1: Flow chart of included studies 133 
 134 
3.2 Study Characteristics  135 
Country CWP prevalence data (Table 2) is from the UK (N=9) (Benjamin et al., 2000; 136 
Carnes et al., 2007; Choudhury et al., 2013; Croft et al., 1993; Flüß et al., 2015; Hunt 137 
et al., 1999; Lee et al., 2010; Macfarlane et al., 1999; Macfarlane et al., 2009a; 138 
Macfarlane et al., 2009b; Pang et al., 2010; Papageorgiou et al., 2002; Vandenkerkhof 139 
et al., 2011; Walker-Bone et al., 2016), Spain (N=4) (Bannwarth et al., 2009; Branco 140 





et al., 2010; Dueñas et al., 2016; Dueñas et al., 2015; Lee et al., 2010; Macfarlane et 141 
al., 2009b; Mas et al., 2008), Brazil (N=3) (Assumpção et al., 2009; Cabral et al., 142 
2014; Santos et al., 2010), Sweden (N=4) (Bergman et al., 2001; Dragioti et al., 2016; 143 
Gerdle et al., 2008; Lee et al., 2010; Lindell et al., 2000; Macfarlane et al., 2009b), 144 
US (N=2) (Riskowski 2014; Wolfe et al., 1995), France (N=2) (Bannwarth et al., 145 
2009; Branco et al., 2010; Perrot et al., 2011), Germany (N=2) (Bannwarth et al., 146 
2009; Branco et al., 2010; Schochat and Raspe 2003), Israel (N=2) (Ablin et al., 2012; 147 
Buskila et al., 2000), Italy (N=2) (Bannwarth et al., 2009; Branco et al., 2010; Lee et 148 
al., 2010; Macfarlane et al., 2009b), Norway (N=2) (Abusdal et al., 1997a; Abusdal et 149 
al., 1997b; Hagen et al., 2005), Belgium (N=1) (Lee et al., 2010; Macfarlane et al., 150 
2009b), Canada (N=1) (White et al., 1999), Estonia (N=1) (Lee et al., 2010; 151 
Macfarlane et al., 2009b), Hong Kong (N=1) (Scudds et al., 2006), Hungary (N=1) 152 
(Lee et al., 2010; Macfarlane et al., 2009b), Netherlands (N=1) (Picavet and Schouten 153 
2003), Poland (N=1) (Lee et al., 2010; Macfarlane et al., 2009b), Portugal (N=1) 154 
(Bannwarth et al., 2009; Branco et al., 2010) and Turkey (N=1) (Topbas et al., 2005).  155 
The included studies varied in terms of CWP definition, survey method and 156 
measurement processes (Table S2). CWP was identified using the ACR criteria 157 
(N=24) (Wolfe et al., 1990), the Manchester definition (N=3), and a study-specific 158 
definition (N=5). CWP data were collected by postal survey (N=10) (Abusdal et al., 159 
1997a; Abusdal et al., 1997b; Bergman et al., 2001; Carnes et al., 2007; Croft et al., 160 
1993; Dragioti et al., 2016; Flüß et al., 2015; Gerdle et al., 2008; Hagen et al., 2005; 161 
Lindell et al., 2000; Papageorgiou et al., 2002; Picavet and Schouten 2003), telephone 162 
(N=1) (Dueñas et al., 2016; Dueñas et al., 2015) face-to-face interviews (N=2) 163 
(Cabral et al., 2014; Mas et al., 2008), clinical examination (N=1) (Santos et al., 164 
2010), touch screen questionnaire (N=1) (Walker-Bone et al., 2016) or combined 165 





methods (N=15) (Ablin et al., 2012; Assumpção et al., 2009; Bannwarth et al., 2009; 166 
Benjamin et al., 2000; Branco et al., 2010; Buskila et al., 2000; Choudhury et al., 167 
2013; Hunt et al., 1999; Lee et al., 2010; Macfarlane et al., 1999; Macfarlane et al., 168 
2009a; Macfarlane et al., 2009b; Pang et al., 2010; Perrot et al., 2011; Riskowski 169 
2014; Schochat and Raspe 2003; Scudds et al., 2006; Topbas et al., 2005; 170 
Vandenkerkhof et al., 2011; White et al., 1999; Wolfe et al., 1995).  171 
 172 
3.3 Chronic Widespread Pain Prevalence  173 
The included 30 studies provided 41 prevalence estimates of CWP. From the included 174 
manuscripts, overall CWP sample prevalence, ranged from 1.4% in the UK (Walker-175 
Bone et al., 2016) to 24.0% in Brazil (Assumpção et al., 2009). In combining the 176 
studies where sample prevalence data was available and excluding any studies with 177 
single gender analysis, a total of 622,169 participants across 26 studies were included 178 
in the analysis, and the estimated overall CWP prevalence was 9.6% (95% confidence 179 
interval [CI]: 8.0-11.2%). 180 
 181 
3.4 Gender 182 
Four studies were of a single gender, one of men only (Lee et al., 2010; Macfarlane et 183 
al., 2009b) and three of women only (Abusdal et al., 1997a; Abusdal et al., 1997b; 184 
Schochat and Raspe 2003; Topbas et al., 2005), while eleven studies provided 185 
estimates from both genders in the general population. In the single gender studies, 186 
CWP prevalence in men was estimated at 8.3%, with data only available from a CWP 187 
study in Europe (Lee et al., 2010; Macfarlane et al., 2009b), while in women CWP 188 
prevalence ranged from 13.5% in Germany (Schochat and Raspe 2003) to 22.1% in 189 





Norway (Abusdal et al., 1997a; Abusdal et al., 1997b). When combining women-only 190 
studies (n=6805), the CWP prevalence in women was 17.3% (16.4-18.1%).  191 
Where studies included data for both genders, the prevalence in men ranged 192 
from 0.8% in Sweden (Dragioti et al., 2016) to 15.3% in Estonia (Lee et al., 2010; 193 
Macfarlane et al., 2009b), and in women it ranged from 1.7% (Walker-Bone et al., 194 
2016) to 15.6% (Croft et al., 1993), with both study CWP estimates coming from the 195 
UK. When combining the data for men (n=242,808), the estimated overall CWP 196 
prevalence was 7.2% (5.5-8.9%), while in women, (n=291,129) the estimated overall 197 
CWP prevalence was 11.2% (8.3-14.2%). Univariate regression analysis by gender 198 
found women had a significantly higher CWP prevalence relative to men (p<0.01; 199 
Table 3). 200 
 201 
3.5 Age 202 
Age-specific data was provided in 14 studies (Abusdal et al., 1997a; Abusdal et al., 203 
1997b; Bannwarth et al., 2009; Benjamin et al., 2000; Bergman et al., 2001; Branco et 204 
al., 2010; Buskila et al., 2000; Carnes et al., 2007; Croft et al., 1993; Dragioti et al., 205 
2016; Dueñas et al., 2016; Dueñas et al., 2015; Gerdle et al., 2008; Hunt et al., 1999; 206 
Lee et al., 2010; Lindell et al., 2000; Macfarlane et al., 1999; Macfarlane et al., 207 
2009b; Mas et al., 2008; Picavet and Schouten 2003; Walker-Bone et al., 2016). Due 208 
to the variability in each of the available studies age bandings it was not possible to 209 
combine the data for further analysis. Of studies evaluating CWP by age, nine 210 
reported an increase in pain prevalence with age (Abusdal et al., 1997a; Abusdal et 211 
al., 1997b; Benjamin et al., 2000; Bergman et al., 2001; Buskila et al., 2000; Croft et 212 
al., 1993; Dueñas et al., 2016; Dueñas et al., 2015; Gerdle et al., 2008; Hunt et al., 213 
1999; Lindell et al., 2000; Macfarlane et al., 1999; Picavet and Schouten 2003), while 214 





four reported a decrease or levelling out of pain prevalence from 50-60 years only to 215 
increase again from 60 years (Croft et al., 1993; Dragioti et al., 2016; Lee et al., 2010; 216 
Macfarlane et al., 2009b; Mas et al., 2008).  217 
 218 
3.6 Survey Method 219 
Methods of data collection varied between studies, with sixteen studies using a single 220 
style of data collection (i.e., telephone, face-to-face or clinical/physical exam) and 221 
fourteen using a combined method (postal or telephone with clinical/physical 222 
examination). The method of survey was further grouped into a personal (face-to-223 
face, telephone and clinical examination) and non-personal (postal survey) approach 224 
for further analysis. Seventeen studies with 21 CWP estimates (n=546,553) were 225 
included in the personal group, while nine studies (n=75,616) were included in the 226 
non-personal survey method. Random-effects CWP prevalence estimates between 227 
personal and non-personal were similar (9.9% [7.5-12.3%] v 7.6% [4.7-10.4%,], 228 
p=0.981).  229 
 230 
3.7 Region  231 
By WHO regions (Figure 2), there were nineteen studies of CWP prevalence in 232 
Europe, five of the Americas, and one in Western Pacific. Combining country data for 233 
Europe and the Americas revealed overall CWP prevalence estimates were similar 234 
(8.9% [6.9-10.9%] v 10.9% [5.1-16.7%], p=0.497).  235 
 236 
Figure 2: Geographical spread of CWP prevalence 237 
 238 
 239 





3.8 Development status, HDI Index and GINI Index 240 
Contextual factors of socioeconomic position included the UN development status, 241 
HDI and GINI Index. Based on the country’s UN development status, there were 27 242 
CWP estimates (n=620,214) from developed countries, and the CWP prevalence of 243 
8.6% (6.9-10.3%). Three CWP estimates were from developing countries (n=1955), 244 
and the CWP prevalence estimate for these countries was 14.5% (3.9-25.1%). The 245 
meta-regression showed UN development status relating to CWP prevalence 246 
(p=0.041), which was similar to the HDI results that countries with a higher the HDI 247 
(i.e., more developed country) had a lower reported CWP prevalence (p=0.001). 248 
 249 
3.9 Methodological Quality 250 
Quality scores ranged from 6/12 to 12/12 (Table S3), with 10 manuscripts being noted 251 
as having low quality (≤8/12) (Abusdal et al., 1997a; Abusdal et al., 1997b; Gerdle et 252 
al., 2008; Pang et al., 2010; Papageorgiou et al., 2002; Perrot et al., 2011; Picavet and 253 
Schouten 2003; Scudds et al., 2006; Vandenkerkhof et al., 2011; White et al., 1999) 254 
and 29 of high quality (≥9/12) (Ablin et al., 2012; Assumpção et al., 2009; Bannwarth 255 
et al., 2009; Benjamin et al., 2000; Bergman et al., 2001; Branco et al., 2010; Buskila 256 
et al., 2000; Cabral et al., 2014; Carnes et al., 2007; Cho et al., 2012; Choudhury et 257 
al., 2013; Croft et al., 1993; Dragioti et al., 2016; Dueñas et al., 2016; Dueñas et al., 258 
2015; Flüß et al., 2015; Hagen et al., 2005; Hunt et al., 1999; Lee et al., 2010; 259 
Leveille et al., 2001; Lindell et al., 2000; Macfarlane et al., 1999; Macfarlane et al., 260 
2009a; Macfarlane et al., 2009b; Mas et al., 2008; Riskowski 2014; Santos et al., 261 
2010; Schochat and Raspe 2003; Topbas et al., 2005; Walker-Bone et al., 2016; 262 
Wolfe et al., 1995). Most of the included manuscripts (N=37) consistently identified 263 
the CWP outcome measure and study eligibility criteria. Lack of appropriate reporting 264 





was in reporting bias and providing detailed methodology. When addressing bias, 265 
only five manuscripts identified their methods for controlling bias, 18 failed to 266 
provide their adjusted estimates and precision (e.g., 95% confidence interval) for 267 
CWP prevalence, and 27 did not report data collection methods and participant 268 
recruitment. The high-quality studies (n=592,034) had a CWP prevalence of 9.7% 269 
(7.4-12.1%), while the low-quality studies (n=30,135) had a similar (p=0.242) CWP 270 
prevalence estimate of 7.5% (5.3-9.6%). 271 
 272 
  273 





4.0 Discussion 274 
 275 
The current review aimed to determine the global prevalence of CWP in the general 276 
population. The review identified 30 studies with 41 estimates of CWP prevalence. 277 
From these CWP studies, global CWP prevalence estimate was 9.6% (95% CI: 8.4-278 
11.2%). Women were found to have a higher CWP prevalence than men (11.2% v 279 
7.2%). In identifying other factors associated with CWP prevalence, data collection 280 
style of personal or non-personal approach showed no significant effect, but the 281 
personal approach (i.e., face-to-face, telephone, examination) tended to increase CWP 282 
prevalence compared to non-personal (9.9% v 7.6%). Additionally, countries with a 283 
higher human development index (HDI) had a lower CWP prevalence compared to 284 
lower HDI countries (8.6% v 14.5%). Results from this work suggest there is a 285 
significant burden of CWP on the general population, particularly among women, and 286 
that improving a country’s standard of living, as indicated by the HDI, may influence 287 
CWP prevalence.  288 
 289 
4.1 Diagnostic Criteria 290 
CWP diagnosis originally came from the ACR 1990 criteria of FMS. However, 291 
recently the Manchester criteria, which requires pain to be found in two locations of 292 
two contralateral limbs and also in the axial skeleton (Okifuji and Hare 2014), is 293 
gaining traction. Although, the ACR 1990 and Manchester definitions allow 294 
standardisation and comparisons to be made (Okifuji and Hare 2014), results of CWP 295 
prevalence by these two definitions are not similar. Gerdle et al (Gerdle et al., 2008) 296 
found CWP to be 7.4% when applying the Manchester criteria, while they only 297 
recorded 4.8% with ACR. In contrast the Manchester cohort (Benjamin et al., 2000; 298 





Hunt et al., 1999; Macfarlane et al., 1999) found CWP to be 4.7% with the 299 
Manchester criteria and 12.9% with the ACR definition. Between these studies 300 
sample sizes were different (n=1953 (Benjamin et al., 2000; Hunt et al., 1999; 301 
Macfarlane et al., 1999) v n=7637 (Gerdle et al., 2008)), but these two studies also 302 
differed in the number of pain sites the study participant could select in the pain chart. 303 
The Manchester group (Benjamin et al., 2000; Hunt et al., 1999; Macfarlane et al., 304 
1999) had 26 pain sites available versus 17 in the Gerdle et al study (Gerdle et al., 305 
2008). The number of pain sites available to select could not only lead to participant 306 
confusion, but it could also lead to participants under or over-reporting the number of 307 
pain site depending on if their specific pain site is not provided. Research evaluating 308 
style of pain reported has suggested that the most efficient method for assessing this is 309 
through the completion of a body manikin (Croft 2002) or through the number of pain 310 
sites rather than the location of pain (Beasley and Macfarlane 2014), which is what 311 
the ACR 2010 definition does. As such, future research should aim to determine a 312 
uniform diagnosis for CWP that utilises a body manikin with a set number of pain 313 
sites to ensure prevalence figures are reliable and can be comparable across studies.  314 
 315 
4.2 Age and Gender 316 
The current review found no significant difference in CWP by age group. However, 317 
part of the lack of effect may be due to few studies reporting CWP prevalence by 318 
similar age group bandings. Given the inconsistencies in age group reporting it is 319 
difficult to determine accurate CWP prevalence estimates, and future studies should 320 
aim to report specific prevalence estimates for age using consistent age banding.  321 
Studies have consistently shown that women experience more pain than men 322 
(Bartley and Fillingim 2016; Fillingim et al., 2009; Pieretti et al., 2016). This review 323 





found similar results, with the meta-analysis showing CWP was higher in women 324 
compared to men (11.4% v 7.2%). Reasons for the gender differences in pain are 325 
often hypothesised to be biological, but studies have also suggested that differences in 326 
pain may relate to psychological or social factors (Wiesenfeld-Hallin 2005) as some 327 
men may fear they will appear weak if they express their pain (Fillingim et al., 2009). 328 
Researchers hypothesise that while women score higher on pain, they are often 329 
encouraged to talk about their feelings and may be more comfortable than men at 330 
indicating they are experiencing pain (Fillingim et al., 2009).  331 
 332 
4.3 Geographical region 333 
Although there were no regional variations of CWP prevalence noted by the meta-334 
regression, these results should be viewed with caution, as regions other than Europe 335 
and the Americas were not well represented. The prior CWP review (Mansfield et al., 336 
2016) noted differences between Europe and America, with Europe having a higher 337 
CWP prevalence than the Americas (12.8% v 7.1%). These prior results are in 338 
contrast with the current study where it shows a non-significant difference between 339 
regions (8.9% in Europe v 10.9% in Americas). A possible explanation for this CWP 340 
difference could be the variation in the studies included between the two reviews. For 341 
example, this review included only general population studies, not studies of specific 342 
populations within the larger population. As such, the prior meta-analysis (Mansfield 343 
et al., 2016) included a CWP study of a Native American population (Jacobsson et al., 344 
1996), a small sub-population within the US general population, but did not include a 345 
large population-based National Health and Nutrition Examination Survey 346 
(NHANES) study (Riskowski 2014), suggesting the current and prior CWP 347 
systematic review focused on different study populations.  348 





4.4 Socioeconomics Position and CWP 349 
The novelty of this meta-analysis was in the analyses of socioeconomic position 350 
measures to CWP prevalence. The socioeconomic position contextual factors were the 351 
HDI (HDR 2016), United Nations (UN) developed/developing country definition (UN 352 
2012), and GINI index (HDR 2016). Although the HDI and UN definition of 353 
developed/developing countries may appear similar, the HDI is a composite index 354 
based on life expectancy, education level, and per capita income indicators, whereas 355 
the UN definition of developed and developing countries is “intended to reflect basic 356 
economic country conditions” rather than consideration of life within the country 357 
(United Nations United Nations Department of Economic and Social Affairs (US 358 
DESA) 2012).  359 
Within the work presented, the dichotomised UN-defined developed versus 360 
developing country showed higher CWP prevalence within the developing countries 361 
(p=0.04). The results of less developed countries having greater prevalence of CWP 362 
aligned to results of the continuous HDI variable, which showed countries with a 363 
higher HDI (more developed countries) having a lower CWP prevalence.  The results 364 
of a higher HDI (e.g., developed countries) associated with lower prevalence of pain 365 
aligns with other studies evaluating socioeconomic position with chronic pain (Urwin 366 
et al., 1998) and adds further evidence that socioeconomic position is associated with 367 
health (Braveman et al., 2010b) and pain (Riskowski 2014).  368 
Studies have suggested that financial strain and lower socioeconomic 369 
conditions can result in stress-induced muscular tension and pain (Soares and 370 
Jablonska 2004). At the individual-level, poor coping strategies to stress, leading to 371 
muscular tension, is believed to play a role in the higher rates of chronic pain in those 372 
in a lower socioeconomic position relative to their higher counterparts (Ridder De 373 





2000; Roth and Geisser 2002). Extrapolating the individual-level measure of 374 
socioeconomic position to the contextual population-level measure (e.g., HDI), poor 375 
community and support structures that provide mechanisms to assist people in coping 376 
with stress may explain the population-level association of CWP to lower 377 
socioeconomic conditions. Given the low number of studies from developing and 378 
lower socioeconomic countries, there is a need for epidemiological studies of chronic 379 
pain in these regions to determine the global prevalence of CWP and to evaluate the 380 
effect of the country’s socioeconomic position with respect to CWP prevalence.   381 
 382 
4.5 Strengths and limitations 383 
Although there is a relatively recent review examining global prevalence of CWP 384 
(Mansfield et al., 2016), this review adds to their results by examining a number of 385 
contextual factors that may impact the CWP prevalence, such as the HDI, survey 386 
method, and WHO region.  However, other factors not accounted in this review were 387 
race and ethnicity, due to the lack of reported data. Future studies, where appropriate, 388 
should include race and ethnicity information of participants as some studies have 389 
suggested it may impact risk of CWP (Allison et al., 2002; Macfarlane et al., 2005). 390 
Along these same lines, studies have also suggested that class or socioeconomic 391 
position may also be an individual factor that relates to risk of chronic pain (Rios and 392 
Zautra 2011; Urwin et al., 1998), but within the systematic review there was one 393 
study that evaluated CWP by class or social position. Thus, the surrogate markers of 394 
HDI and the WHO development status were used to evaluate the effect of social 395 
deprivation at the country-level, with results suggesting that with greater social 396 
deprivation there is greater risk of CWP. However, the country-level marker may not 397 
truly represent the participants in the study, and future work should evaluate health 398 





status along social strata in addition to racial and ethnic categories (Braveman et al., 399 
2010a).  400 
 401 
4.6 Conclusion 402 
Results of this systematic review indicate that CWP affects one in ten individuals 403 
globally within the general population. In 30 studies across 19 countries women were 404 
found to have a higher CWP prevalence than men, and those in countries with a lower 405 
HDI tended to be more likely to experience CWP than those in a high HDI country. 406 
To further evaluate CWP, research is needed by other individual-level factors (e.g., 407 
race, ethnicity) with a greater range of developing and developed countries.   408 
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